中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 38 Issue 1
Jan.  2022
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2022  >  38(1): 201-205

Research advances in in vitro models for nonalcoholic fatty liver disease

DOI: 10.3969/j.issn.1001-5256.2022.01.035

  • Department of Gastroenterology, The Affiliated Hospital of Yanbian University, Yanji, Jilin 133000, China

Research funding:

National Natural Science Foundation of China (81860110)

  • Received Date: 2021-05-19
  • Accepted Date: 2021-06-03
  • Published Date: 2022-01-20
    Abstract
  • The incidence rate of nonalcoholic fatty liver disease (NAFLD) is increasing year by year, with limited treatment methods, and its pathogenesis is a research hotspot at present. In order to better clarify its pathogenesis, it is urgent to develop advanced, safe, and effective in vitro or in vivo models to understand and develop treatment strategies for this disease. This article reviews the in vitro models commonly used in the preclinical study of NAFLD and discusses their advantages and disadvantages, so as to provide a theoretical basis for the pathogenesis and treatment of NAFLD.

     

    • FullText(HTML)
  • loading
    • References(44)
  • [1]
    OVERI D, CARPINO G, FRANCHITTO A, et al. Hepatocyte injury and hepatic stem cell niche in the progression of non-alcoholic steatohepatitis[J]. Cells, 2020, 9(3): 590. DOI: 10.3390/cells9030590.
    [2]
    LIU W, BAKER RD, BHATIA T, et al. Pathogenesis of nonalcoholic steatohepatitis[J]. Cell Mol Life Sci, 2016, 73(10): 1969-1987. DOI: 10.1053/j.gastro.2016.02.066.
    [3]
    ULLAH R, RAUF N, NABI G, et al. Role of nutrition in the pathogenesis and prevention of non-alcoholic fatty liver disease: Recent updates[J]. Int J Biol Sci, 2019, 15(2): 265-276. DOI: 10.7150/ijbs.30121.
    [4]
    IPSEN DH, TVEDEN-NYBORG P. Extracellular vesicles as drivers of non-alcoholic fatty liver disease: Small particles with big impact[J]. Biomedicines, 2021, 9(1): 93. DOI: 10.3390/biomedicines 9010093.
    [5]
    PAN X, QUEIROZ J, HUSSAIN MM. Nonalcoholic fatty liver disease in CLOCK mutant mice[J]. J Clin Invest, 2020, 130(8): 4282-4300. DOI: 10.1172/JCI132765.
    [6]
    KIM WR, LAKE JR, SMITH JM, et al. OPTN/SRTR 2016 annual data report: Liver[J]. Am J Transplant, 2018, 18(Suppl 1): 172-253. DOI: 10.1111/ajt.14559.
    [7]
    TILG H, ADOLPH TE, MOSCHEN AR. Multiple parallel hits hypothesis in nonalcoholic fatty liver disease: Revisited after a decade[J]. Hepatology, 2021, 73(2): 833-842. DOI: 10.1002/hep.31518.
    [8]
    WILLEBRORDS J, PEREIRA IV, MAES M, et al. Strategies, models and biomarkers in experimental non-alcoholic fatty liver disease research[J]. Prog Lipid Res, 2015, 59: 106-125. DOI: 10.1016/j.plipres.2015.05.002.
    [9]
    HUANG F, ZHAO S, YU F, et al. Protective effects and mechanism of meretrix meretrix oligopeptides against nonalcoholic fatty liver disease[J]. Mar Drugs, 2017, 15(2): 31. DOI: 10.3390/md15020031.
    [10]
    ZEILINGER K, FREYER N, DAMM G, et al. Cell sources for invitro human liver cell culture models[J]. Exp Biol Med (Maywood), 2016, 241(15): 1684-1698. DOI: 10.1177/1535370216657448.
    [11]
    SORET PA, MAGUSTO J, HOUSSET C, et al. In vitro and in vivo models of non-alcoholic fatty liver disease: A critical appraisal[J]. J Clin Med, 2020, 10(1): 36. DOI: 10.3390/jcm10010036.
    [12]
    HE WX, YANG JY, XU YJ, et al. Establishment and evaluation of a fructose-induced hepatic steatosis cell model[J]. Chin Hepatol, 2019, 24(6): 638-642. DOI: 10.3969/j.issn.1008- 1704.2019.06.018.

    贺雯茜, 杨金玉, 徐艳娇, 等. 果糖诱导肝脂肪变性细胞模型建立及评价[J]. 肝脏, 2019, 24(6): 638-642. DOI: 10.3969/j.issn.1008-1704.2019.06.018.
    [13]
    JU L, SUN Y, XUE H, et al. CCN1 promotes hepatic steatosis and inflammation in non-alcoholic steatohepatitis[J]. Sci Rep, 2020, 10(1): 3201. DOI: 10.1038/s41598-020-60138-8.
    [14]
    ZHOU L, TANG J, YANG X, et al. Five constituents in psoralea corylifolia L. Attenuate palmitic acid-induced hepatocyte injury via inhibiting the protein kinase c-α/nicotinamide-adenine dinu cleotide phosphate oxidase pathway[J]. Front Pharmacol, 2020, 10: 1589. DOI: 10.3389/fphar.201 9.01589.
    [15]
    WILLEBRORDS J, PEREIRA IV, MAES M, et al. Strategies, models and biomarkers in experimental non-alcoholic fatty liver disease research[J]. Prog Lipid Res, 2015, 59: 106-125. DOI: 10.1016/j.plipres.2015.05.002.
    [16]
    LUO Y, HE XP, LI X, et al. Establishment and comparative analysis of several kinds of cell fatty degeneration model[J]. Chin Arch Tradit Chin Med, 2017, 35(8): 2074-2077. DOI: 10.13193/j.issn.1673-7717.2017.08.040.

    罗燕, 和兴萍, 李雪, 等. 几种细胞脂肪变性模型的建立与比较分析[J]. 中华中医药学刊, 2017, 35(8): 2074-2077. DOI: 10.13193/j.issn.1673-7717.2017.08.040.
    [17]
    ANINAT C, PITON A, GLAISE D, et al. Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells[J]. Drug Metab Dispos, 2006, 34(1): 75-83. DOI: 10.1124/dmd.105.006759.
    [18]
    HU C, LI L. In vitro culture of isolated primary hepatocytes and stem cell-derived hepatocyte-like cells for liver regeneration[J]. Protein Cell, 2015, 6(8): 562-574. DOI: 10.1007/s13238-015-0180-2.
    [19]
    ROBINTON DA, DALEY GQ. The promise of induced pluripotent stem cells in research and therapy[J]. Nature, 2012, 481(7381): 295-305. DOI: 10.1038/nature10761.
    [20]
    DEEPAK HB, SHREEKRISHNA N, SAMEERMAHMOOD Z, et al. An in vitro model of hepatic steatosis using lipid loaded induced pluripotent stem cell derived hepatocyte like cells[J]. J Biol Methods, 2020, 7(3): e135. DOI: 10.14440/jbm.2020.330.
    [21]
    WONG VW, ADAMS LA, de LÉDINGHEN V, et al. Noninvasive biomarkers in NAFLD and NASH - current progress and future promise[J]. Nat Rev Gastroenterol Hepatol, 2018, 15(8): 461-478. DOI: 10.1038/s41575-018-0014-9.
    [22]
    LYALL MJ, CARTIER J, THOMSON JP, et al. Modelling non-alcoholic fatty liver disease in human hepatocyte-like cells[J]. Philos Trans R Soc Lond B Biol Sci, 2018, 373(1750): 20170362. DOI: 10.1098/rstb.2017.0362.
    [23]
    MAZZOLENI G, DI LORENZO D, STEIMBERG N. Modelling tissues in 3D: The next future of pha rmaco-toxicology and food research?[J]. Genes Nutr, 2009, 4: 13-22. DOI: 10.1007/s12263-008-0107-0.
    [24]
    GREEN CJ, PRAMFALK C, MORTEN KJ, et al. From whole body to cellular models of hepatic triglyceride metabolism: Man has got to know his limitations[J]. Am J Physiol Endocrinol Metab, 2015, 308(1): E1-E20. DOI: 10.1152/ajpendo.00192.2014.
    [25]
    KRAUSE P, SAGHATOLISLAM F, KOENIG S, et al. Maintaining hepatocyte differentiation in vitro through co-culture with hepatic stellate cells[J]. In Vitro Cell Dev Biol Anim, 2009, 45: 205-212. DOI: 10.1016/j.stem.2018.05.027.
    [26]
    BARBERO-BECERRA VJ, GIRAUDI PJ, CHÁVEZ-TAPIA NC, et al. The interplay between hepatic stellate cells and hepatocytes in an in vitro model of NASH[J]. Toxicol In Vitro, 2015, 29(7): 1753-1758. DOI: 10.1016/j.tiv.2015.07.010.
    [27]
    ANFUSO B, GIRAUDI PJ, TIRIBELLI C, et al. Silybin modulates collagen turnover in an in vitro model of NASH[J]. Molecules, 2019, 24(7): 280. DOI: 10.3390/molecules24071280.
    [28]
    JAIN MR, GIRI SR, BHOI B, et al. Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models[J]. Liver Int, 2018, 38(6): 1084-1094. DOI: 10.1111/liv.13634.
    [29]
    BALE SS, GOLBERG I, JINDAL R, et al. Long-term coculture strategies for primary hepatocytes and liver sinusoidal endothelial cells[J]. Tissue Eng Part C Methods, 2015, 21(4): 413-422. DOI: 10.1089/ten.TEC.2014.0152.
    [30]
    KOZYRA M, JOHANSSON I, NORDLING Å, et al. Human hepatic 3D spheroids as a model for steatosis and insulin resistance[J]. Sci Rep, 2018, 8(1): 14297. DOI: 10.1038/s41598-018-32722-6.
    [31]
    MUKHERJEE S, ZHELNIN L, SANFIZ A, et al. Development and validation of an in vitro 3D model of NASH with severe fibrotic phenotype[J]. Am J Transl Res, 2019, 11(3): 1531-1540. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6456529/
    [32]
    PINGITORE P, SASIDHARAN K, EKSTRAND M, et al. Human multilineage 3D spheroids as a model of liver steatosis and fibrosis[J]. Int J Mol Sci, 2019, 20(7): 1629. DOI: 10.3390/ijms20071629.
    [33]
    HURRELL T, KASTRINOU-LAMPOU V, FARDELLAS A, et al. Human liver spheroids as a model to study aetiology and treatment of hepatic fibrosis[J]. Cells, 2020, 9(4): 964. DOI: 10.3390/cells 9040964.
    [34]
    KIM J, KOO BK, KNOBLICH JA. Human organoids: Model systems for human biology and medicine[J]. Nat Rev Mol Cell Biol, 2020, 21(10): 571-584. DOI: 10.1038/s41580-020-0259-3.
    [35]
    OUCHI R, TOGO S, KIMURA M, et al. Modeling steatohepatitis in humans with pluripotent stem cell-derived organoids[J]. Cell Metab, 2019, 30: 374-384. e6. DOI: 10.1016/j.cmet.2019.05. 007.
    [36]
    KRUITWAGEN HS, OOSTERHOFF LA, VERNOOIJ I, et al. Long-term adult feline liver organoid cultures for disease modeling of hepatic steatosis[J]. Stem Cell Reports, 2017, 8(4): 822-830. DOI: 10.1016/j.stemcr.2017.02.015.
    [37]
    HAAKER MW, KRUITWAGEN HS, VAANDRAGER AB, et al. Identification of potential drugs for treatment of hepatic lipidosis in cats using an in vitro feline liver organoid system[J]. J Vet Intern Med, 2020, 34: 132-138. DOI: 10.1016/j.stemcr.2017.02.015.
    [38]
    WANG Y, WANG H, DENG P, et al. Modeling human nonalcoholic fatty liver disease (NAFLD) with an organoids-on-a-chip system[J]. ACS Biomater Sci Eng, 2020, 6(10): 5734-5743. DOI: 10.1021/acsbiomaterials.0c00682.
    [39]
    WANG L, QIU YL, WANG JS. Advances in research and application of liver organoids[J]. J Clin Hepatol, 2019, 35(10): 2342-2345. DOI: 10.3969/j.issn.1001-5256.2019.10.047.

    王利, 丘倚灵, 王建设. 肝类器官研究及应用进展[J]. 临床肝胆病杂志, 2019, 35(10): 2342-2345. DOI: 10.3969/j.issn.1001-5256.2019.10.047.
    [40]
    GORI M, SIMONELLI MC, GIANNITELLI SM, et al. Investigating nonalcoholic fatty liver disease in a liver-on-a-chip microfluidic device[J]. PLoS One, 2016, 11(7): e0159729. DOI: 10.1371/journal.pone.0159729.
    [41]
    LEE SY, SUNG JH. Gut-liver on a chip toward an in vitro model of hepatic steatosis[J]. Biotechnol Bioeng, 2018, 115(11): 2817-2827. DOI: 10.1002/bit.26793.
    [42]
    FREAG MS, NAMGUNG B, GHERARDI E, et al. Human nonalcoholic steatohepatitis on a chip[J]. Hepatol Commun, 2020, 5(2): 217-233. DOI: 10.1002/adbi.201900104.
    [43]
    PALMA E, DOORNEBAL EJ, CHOKSHI S. Precision-cut liver slices: A versatile tool to advance liver research[J]. Hepatol Int, 2019, 13(1): 51-57. DOI: 10.1007/s12072-018-9913-7.
    [44]
    PRINS GH, LUANGMONKONG T, OOSTERHUIS D, et al. A pathophysiological model of non-alcoholic fatty liver disease using precision-cut liver slices[J]. Nutrients, 2019, 11(3): 507. DOI: 10.3390/nu11030507.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (845) PDF downloads(162) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return